Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete Remission
Status:
Completed
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
This research is being done to find out if the investigators can improve outcomes for
multiple myeloma patients by giving a myeloma vaccine to patients who are already on
lenalidomide (Revlimid) and in a near complete remission.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins